The schedule for UBEC 2018 will include exciting and educational presentations and events spanning the diverse fields of biomedical engineering.
We are honored to announce that Dr. Robin Shandas will present the Keynote Address for the 2018 Utah Biomedical Engineering Conference. Dr. Shandas is the Professor and Founding Chairman of the Department of Bioengineering at the University of Colorado Denver and Director of the Center for Bioengineering and Professor of Pediatrics and Surgery at the University of Colorado School of Medicine Dr. Shandas’ research revolves around 3 key areas: 1) congenital heart disease, with focus on diagnostics and mechanics of pediatric pulmonary hypertension; 2) novel imaging and modeling techniques including ultrasound, MRI and use of 3D printing to facilitate clinical diagnostics and treatment; 3) new biomaterials, including shape memory polymers. He directs multiple research and training grants including a long-standing NIH T32 training grant in Cardiovascular Biomechanics and Imaging, several large NIH grants on pulmonary vascular disease, and is one of the few PhD scientists to receive the NIH K24 award for patient-oriented research. He has mentored over 60 graduate students, post-doctoral fellows, and junior faculty. A firm believer in moving research into the clinic, Shandas is also an active, serial, med-tech entrepreneur. His inventions include an artificial right ventricle for treating children with failing Fontan, a new echo particle image velocimetry technique for measuring blood flow shear stress, and new shape memory polymers for minimally invasive medical devices. These and other inventions resulted in the formation of 8 startup companies, with several successful exits. One of his companies, Endoshape Inc., received FDA approval for a shape memory polymer endovascular embolization device; the device has now been used in over 800 patients. Polymer-based technologies from two ophthalmic startups were acquired by Abbott Medical Optics (now J&J) and Oasis Medical. Another company, EnteroTrack, recently completed Phase II clinical trials for a novel, minimally-invasive technique (device + companion diagnostic) to monitor esophageal inflammation. A more recent sports-medicine startup, MITA, was acquired by Stryker, a global biotechnology company. Many students have been and continue to be involved in these and upcoming startups. Dr. Shandas obtained his Ph.D. in Bioengineering at the University of California San Diego and his B.S.at University of California Santa Barbara.